<DOC>
	<DOCNO>NCT01569061</DOCNO>
	<brief_summary>The primary objective study determine effectiveness transvaginally-delivered low level laser therapy ( LLLT ) versus Sham treatment overactive bladder symptom woman . The secondary objective determine effect transvaginally-delivered LLLT vs. sham quality life .</brief_summary>
	<brief_title>Painless Laser Therapy Overactive Bladder</brief_title>
	<detailed_description>This study double-blind , randomize , sham-controlled , multicenter , clinical trial include enrollment 200 subject 3 investigational site . The study population randomize 1:1 ratio two group : Sham Laser Group ( SLG ) Active Laser Group ( ALG ) . The Sham Laser Group receive sham LLLT procedure ( laser energy ) Active Laser Group receive active LLLT procedure ( laser energy ) . Both group undergo 3 LLLT procedure per week 3 week , total 9 LLLT procedure . Whether procedure sham procedure ( placebo ) active LLLT application determine randomization assign subject treat LCT-1000TM label either Laser A Laser B . The difference Laser A Laser B one emit laser energy ; therefore , subject site research personnel blind whether laser energy actually apply subject .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>The subject female least 18 year age screening . A score &gt; 4 OABq short form urgency . The subject average urinary frequency &gt; 10 void per day . Selfreported bladder symptom &gt; 3 month . Selfreported fail conservative care . The subject discontinue antimuscarinics least 2 week prior screen . The subject ambulatory able use toilet independently without difficulty . Negative pregnancy test subject childbearing potential . Subject attests write unprotected intercourse within 3 week prior study enrollment agrees intercourse treatment conclude . Subject Informed Consent obtain write compliance local regulation prior enrollment study . The subject ( caregiver , applicable ) willing participate study least 7 week . The subject otherwise general good health major medical condition . The subject vaginal bleeding . The subject urinary gastric retention neurogenic bladder . The subject capable completing study questionnaires undergoing portion study . The subject sexually assault . The subject alcohol drug addiction . The subject use isotretinoin ( Accutane ) within 6 month prior study enrollment . The subject cancer . The subject use Botox® bladder pelvic floor muscle within 12 month prior study enrollment . The subject currently urinary tract infection vaginal infection . The subject use Interstim® Bion® . Current use TENS pelvic region , back leg . The subject pregnant lactating , childbearing potential unless surgically sterile and/or partner use medically acceptable method birth control . Any use lightactivated drug ( photodynamic therapy ) heat sensitive medication within 30 day first treatment . The subject use investigational drug/device therapy participate clinical investigation involve impact gynecologic , urinary , renal function within 4 week prior study enrollment . The subject otherwise determine , base opinion Investigator , unsuitable candidate enrollment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>laser therapy</keyword>
	<keyword>urinary incontinence</keyword>
	<keyword>urinary urgency</keyword>
</DOC>